ACLX Arcellx, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ACLX Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$68.5
Analyst Target
$110.53
+61.4%
Upside
52W High
$94.07
52W Low
$47.86
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 14, 2026
Market cap
$3.96B
P/E
N/A
ROE
-47.2%
Profit margin
N/A
Debt/Equity
0.12
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ACLX exhibits severe financial distress despite a strong analyst consensus, as evidenced by a Piotroski F-Score of 1/9—indicating weak operational and financial health. The company reports negative profitability across all key margins, with a staggering -1248.25% operating margin and -47.18% ROE, while revenue has collapsed by 81% YoY. Although the debt-to-equity ratio is low (0.12) and liquidity is high (current ratio 3.99), these are insufficient to offset deteriorating fundamentals and a bearish insider sentiment. The stock trades at an extreme valuation (Price/Sales 110.34) with no earnings or cash flow support, and insider selling of $5.76M in six months signals lack of confidence. Analysts' strong_buy recommendation appears disconnected from the underlying financial reality.
Key Strengths
Strong analyst consensus with 17 analysts rating 'strong_buy'
High liquidity with current and quick ratios above 3.9
Low debt-to-equity ratio (0.12) indicating minimal leverage risk
Recent insider activity includes small buy signals (though net bearish)
Historical earnings surprise of +184% in Q1 2024 suggests potential for recovery
Key Risks
Piotroski F-Score of 1/9 indicates extreme financial weakness and poor operational efficiency
Revenue declined 81% YoY, signaling business contraction or product failure
Negative operating margin (-1248.25%) and ROE (-47.18%) reflect deep unprofitability
Insider selling of $5.76M in 6 months with no buys indicates loss of confidence
No intrinsic value or Graham Number available, and valuation metrics (P/S 110.34) are unsustainable
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
16
Weak
15
25
30
10
0
AI Verdict
Weak
Key drivers: Extremely low Piotroski F-Score (1/9), Negative and deteriorating revenue and earnings, High valuation without earnings support, Bearish insider activity, No sustainable profitability or cash flow
Confidence
88%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
No standout positives identified.
Watchpoints
- Price/Sales of 110.34 is astronomically high for a company with no revenue growth
- No Graham Number or intrinsic value available due to lack of earnings
- Forward P/E of -19.71 indicates no earnings visibility
- Valuation is purely speculative, not grounded in fundamentals
Future
25/100
Ref Growth rates
Positives
- Analyst target price of $110.53 implies 61% upside from current price
- Some historical earnings surprises were positive (e.g., +184%)
Watchpoints
- Revenue growth is -81% YoY, indicating business contraction
- Earnings growth is -106.2% YoY, with no signs of recovery
- No free cash flow or operating cash flow data available
- Highly speculative growth expectations not supported by current trends
Past
30/100
Ref Historical trends
Positives
- Historical earnings surprise of +184% in Q1 2024
- Some quarters beat estimates (e.g., Q1 2024, Q2 2023)
- Improvement in EPS from prior quarters (e.g., -0.87 to -0.48)
Watchpoints
- Most recent earnings surprises are deeply negative (e.g., -83.4%, -96.2%)
- Consistent underperformance in recent quarters
- EPS has deteriorated significantly over time
- One quarter reported a -557.6% surprise (Q1 2022)
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt-to-equity ratio (0.12)
- High current and quick ratios (3.99 and 3.93)
Watchpoints
- Piotroski F-Score of 1/9 is extremely low, indicating poor financial health
- No Altman Z-Score available, but F-Score suggests distress risk
- Negative ROE and ROA indicate capital inefficiency
- Operating margin is -1248.25%, indicating severe operational losses
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
- Company is not a dividend payer, and not in a position to initiate one
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$68.5
Analyst Target
$110.53
Upside/Downside
+61.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACLX and closest competitors.
Updated 2026-02-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACLX
Arcellx, Inc.
Primary
|
+307.7% | +127.2% | +7.5% | -7.5% | -1.9% | +0.7% |
|
BLLN
BillionToOne, Inc.
Peer
|
-19.6% | -19.6% | -19.6% | -19.6% | +1.4% | -1.3% |
|
ADMA
ADMA Biologics, Inc.
Peer
|
+507.2% | +348.2% | +0.1% | -5.3% | -12.0% | -2.1% |
|
ACAD
ACADIA Pharmaceuticals Inc.
Peer
|
-55.1% | +15.3% | +11.4% | -13.0% | -18.0% | -6.5% |
|
AMRX
Amneal Pharmaceuticals, Inc.
Peer
|
+176.1% | +531.6% | +52.0% | +66.1% | +4.0% | -0.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-19.71
PEG Ratio
N/A
P/B Ratio
8.98
P/S Ratio
110.34
EV/Revenue
98.93
EV/EBITDA
-15.06
Market Cap
$3.96B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-1248.25%
Gross Margin
N/A
ROE
-47.18%
ROA
-21.34%
Growth
Revenue and earnings growth rates
Revenue Growth
-81.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.12
Low debt
Current Ratio
3.99
Strong
Quick Ratio
3.93
Excellent
Cash/Share
$7.98
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-26
$N/A
2025-11-05
$-0.99
+4.1% surprise
2025-08-07
$-0.94
+8.9% surprise
2025-05-08
$-1.13
-53.0% surprise
Healthcare Sector Comparison
Comparing ACLX against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
Return on Equity (ROE)
-47.18%
This Stock
vs
-56.84%
Sector Avg
-17.0%
(Below Avg)
Debt to Equity
0.12
This Stock
vs
2.68
Sector Avg
-95.6%
(Less Debt)
Revenue Growth
-81.0%
This Stock
vs
61.93%
Sector Avg
-230.8%
(Slower)
Current Ratio
3.99
This Stock
vs
3.47
Sector Avg
+15.0%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACLX
Arcellx, Inc.
|
BEARISH | $3.96B | - | -47.2% | -% | $68.5 | |
|
BLLN
BillionToOne, Inc.
|
NEUTRAL | $4.01B | - | -% | -4.4% | $87.57 | |
|
ADMA
ADMA Biologics, Inc.
|
BEARISH | $3.84B | 18.08 | 63.2% | 42.9% | $16.09 | |
|
ACAD
ACADIA Pharmaceuticals Inc.
|
BULLISH | $3.73B | 13.94 | 35.0% | 24.9% | $22.03 | |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
NEUTRAL | $4.21B | 1339.0 | -% | 0.2% | $13.39 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-20 | LUBNER DAVID CHARLES | Director | Sale | 6,000 | $450,000 |
| 2026-01-20 | LUBNER DAVID CHARLES | Director | Option Exercise | 6,000 | $37,680 |
| 2026-01-14 | HEERY CHRISTOPHER RYAN | Officer | Sale | 5,882 | $402,997 |
| 2026-01-13 | HEERY CHRISTOPHER RYAN | Officer | Sale | 7,437 | $487,213 |
| 2026-01-12 | HEERY CHRISTOPHER RYAN | Officer | Sale | 6,131 | $393,286 |
| 2026-01-06 | HEERY CHRISTOPHER RYAN | Officer | Stock Award | 42,605 | - |
| 2026-01-06 | GILSON MICHELLE | Chief Financial Officer | Stock Award | 56,366 | - |
| 2026-01-06 | ELGHANDOUR RAMI | Officer and Director | Stock Award | 164,548 | - |
| 2025-11-17 | HEERY CHRISTOPHER RYAN | Officer | Sale | 340 | $30,600 |
| 2025-10-15 | GILSON MICHELLE | Chief Financial Officer | Sale | 5,364 | $488,315 |
| 2025-10-06 | GILSON MICHELLE | Chief Financial Officer | Sale | 5,946 | $511,603 |
| 2025-09-30 | HEERY CHRISTOPHER RYAN | Officer | Sale | 21,034 | $1,709,723 |
| 2025-09-29 | HEERY CHRISTOPHER RYAN | Officer | Sale | 73 | $5,852 |
| 2025-09-26 | HEERY CHRISTOPHER RYAN | Officer | Sale | 12,396 | $993,155 |
| 2025-09-19 | HEERY CHRISTOPHER RYAN | Officer | Sale | 3,643 | $291,468 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
17 analysts
Needham
2026-02-05
Buy
Buy
HC Wainwright & Co.
2026-02-04
Buy
Buy
Wells Fargo
2025-12-22
Overweight
Canaccord Genuity
2025-12-08
Buy
Buy
Needham
2025-12-08
Buy
Buy
Wolfe Research
2025-11-18
Peer Perform
Canaccord Genuity
2025-11-03
Buy
Buy
Past News Coverage
Recent headlines mentioning ACLX from our newsroom.
Newest → oldest
No matching news yet.